Clinical impact of ibrutinib plus R-CHOP in untreated DLBCL co-expressing BCL2 and MYC in the phase 3 PHOENIX trial
- Categories
- Peer Reviewed Publications
Balasubramanian, S., et al., Comparison of immunohistochemistry and gene expression profiling subtyping for diffuse large B-cell lymphoma in the phase III clinical trial of R-CHOP ± ibrutinib, British Journal of Haematology, https://doi.org/10.1111/bjh.17450
Page last updated May 22, 2023